Periprosthetic joint infection: What is on the horizon?

International Journal of Artificial Organs

Volumn 35, Issue 10, 2012, Pages 935-950

  Hansen, Erik N ^a   Zmistowski, Benjamin ^a   Parvizi, Javad ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Diagnosis; Metabolomics; Periprosthetic joint infection; Prevention; Treatment

Indexed keywords

BIOFILMS; CLINICAL RESEARCH; PHOTODYNAMIC THERAPY;

CLINICAL RESEARCH; COMORBIDITIES; METABOLOMICS; MOLECULAR TECHNIQUES; ORTHOPAEDIC SURGEONS; PERIPROSTHETIC JOINT INFECTION; PREVENTION; TEST DEVELOPMENT; TRANSLATIONAL RESEARCH; TREATMENT;

DIAGNOSIS;

ACETYLCYSTEINE; ANTIBIOTIC AGENT; DNA; ESTERASE; GLYCOLIPID; HYDROXYAPATITE; POLYSACCHARIDE; STAPH VAX; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTHROPLASTY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BIOFILM; BONE IMPLANT; BONE MARROW SCINTISCANNING; COMORBIDITY; DEBRIDEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DRUG DESIGN; EXTRACORPOREAL LITHOTRIPSY; HUMAN; IMMUNE RESPONSE; LAVAGE; LEUKOCYTE; METABOLOMICS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NITINOL STENT; ONE STAGE EXCHANGE ARTHROPLASTY; PERIPROSTHETIC JOINT INFECTION; PHOTODYNAMIC THERAPY; POINT OF CARE TESTING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SEROLOGY; STRATIFIED SAMPLE; SURGICAL INFECTION; TREATMENT OUTCOME; TWO STAGE EXCHANGE ARTHROPLASTY; ULTRASOUND;

EID: 84870535068     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000145     Document Type: Review

References (98)

1. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89(4):780-785.
2. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg Am. 2005;87(8):1746-1751.
3. Parvizi J, Matar WY, Saleh KJ, Schmalzried TP, Mihalko WM. Decolonization of drug-resistant organisms before total joint arthroplasty. Instr Course Lect. 2010;59:131-137.
4. Parvizi J, Jacovides C, Antoci V, Ghanem E. Diagnosis of periprosthetic joint infection: the utility of a simple yet unappreciated enzyme. J Bone Joint Surg Am. 2011;93(24): 2242-2248.
5. Achermann Y, Vogt M, Leunig M, Wüst J, Trampuz A. Improved diagnosis of periprosthetic joint infection by multiplex PCR of sonication fluid from removed implants. J Clin Microbiol. 2010;48(4):1208-1214.
6. Parvizi J, Jacovides C, Zmistowski B, Jung KA. Definition of periprosthetic joint infection: is there a consensus? Clin Orthop Relat Res. 2011;469(11):3022-3030.
7. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res. 2011;469(11):2992-2994.
8. Ghanem E, Parvizi J, Burnett RS, et al. Cell count and differential of aspirated fluid in the diagnosis of infection at the site of total knee arthroplasty. J Bone Joint Surg Am. 2008;90(8):1637-1643.
9. Schinsky MF, Della Valle CJ, Sporer SM, Paprosky WG. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. J Bone Joint Surg Am. 2008;90(9):1869-1875.
10. Bedair H, Ting N, Jacovides C, et al. The Mark Coventry Award: diagnosis of early postoperative TKA infection using synovial fluid analysis. Clin Orthop Relat Res. 2011;469(1):34-40.
11. Spangehl MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J Bone Joint Surg Am. 1999;81(5):672-683.
12. Parvizi J, McKenzie JC, Cashman JP. Diagnosis of Periprosthetic Joint Infection Using Synovial C-Reactive Protein. J Arthroplasty. 2012;27(8 Suppl):12-16.
13. Parvizi J, Jacovides C, Adeli B, Jung KA, Hozack WJ. Coventry Award: synovial C-reactive protein: a prospective evaluation of a molecular marker for periprosthetic knee joint infection. Clin Orthop Relat Res. 2012;470(1):54-60.
14. Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin- 6 as a marker of periprosthetic infection following total hip and knee arthroplasty. J Bone Joint Surg Am. 2005;87(9):1921-1927.
15. Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Götze C. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br. 2007;89(1):94-99.
16. Huang R, Hu CC, Adeli B, Mortazavi J, Parvizi J. Culturenegative Periprosthetic Joint Infection Does Not Preclude Infection Control. Clin Orthop Relat Res. 2012 Jun 26 [Epub ahead of print].
17. Parvizi J, Suh DH, Jafari SM, Mullan A, Purtill JJ. Aseptic loosening of total hip arthroplasty: infection always should be ruled out. Clin Orthop Relat Res. 2011;469(5):1401-1405.
18. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilmresistant materials. Biomaterials. 2012;33(26):5967-5982.
19. Montanaro L, Speziale P, Campoccia D, et al. Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol. 2011;6(11):1329-1349.
20. Costerton JW, Post JC, Ehrlich GD, et al. New methods for the detection of orthopedic and other biofilm infections. FEMS Immunol Med Microbiol. 2011;61(2):133-140.
21. Larsen LH, Lange J, Xu Y, Schønheyder HC. Optimizing culture methods for diagnosis of prosthetic joint infections: a summary of modifications and improvements reported since 1995. J Med Microbiol. 2012;61(Pt 3):309-316.
22. Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs. 2011;34(9):727-736.
23. Rasouli MR, Harandi AA, Adeli B, Purtill JJ, Parvizi J. Revision total knee arthroplasty: infection should be ruled out in all cases. J Arthroplasty. Jun 2012;27(6):1239-1243.e1231-1232.
24. Sorlí L, Puig L, Torres-Claramunt R, et al. The relationship between microbiology results in the second of a two-stage exchange procedure using cement spacers and the outcome after revision total joint replacement for infection: the use of sonication to aid bacteriological analysis. J Bone Joint Surg Br. 2012;94(2):249-253.
25. Hofmann AA, Wyatt RW, Daniels AU, Armstrong L, Alazraki N, Taylor A Jr. Bone scans after total knee arthroplasty in asymptomatic patients. Cemented versus cementless. Clin Orthop Relat Res. 1990;(251):183-188.
26. Reinartz P, Mumme T, Hermanns B, et al. Radionuclide imaging of the painful hip arthroplasty: positron-emission tomography versus triple-phase bone scanning. J Bone Joint Surg Br. 2005;87(4):465-470.
27. Kobayashi N, Inaba Y, Choe H, et al. Use of F-18 fluoride PET to differentiate septic from aseptic loosening in total hip arthroplasty patients. Clin Nucl Med. 2011;36(11):e156-e161.
28. Chryssikos T, Parvizi J, Ghanem E, Newberg A, Zhuang H, Alavi A. FDG-PET imaging can diagnose periprosthetic infection of the hip. Clin Orthop Relat Res. 2008;466(6):1338-1342.
29. Fehring TK, Odum SM, Berend KR, et al. Failure of Irrigation and Debridement for Early Postoperative Periprosthetic Infection. Clin Orthop Relat Res. 2012 May 3 [Epub ahead of print].
30. Greenky M, Gandhi K, Pulido L, Restrepo C, Parvizi J. Preoperative Anemia in Total Joint Arthroplasty: Is It Associated with Periprosthetic Joint Infection? Clin Orthop Relat Res. 2012 Jul 7 [Epub ahead of print].
31. Koyonos L, Zmistowski B, Della Valle CJ, Parvizi J. Infection control rate of irrigation and débridement for periprosthetic joint infection. Clin Orthop Relat Res. 2011;469(11):3043-3048.
32. Mortazavi SM, Vegari D, Ho A, Zmistowski B, Parvizi J. Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure. Clin Orthop Relat Res. 2011;469(11):3049-3054.
33. Rasouli MR, Tripathi MS, Kenyon R, Wetters N, Della Valle CJ, Parvizi J. Low Rate of Infection Control in Enterococcal Periprosthetic Joint Infections. Clin Orthop Relat Res. 2012 May 3 [Epub ahead of print].
34. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39(6):776-782.
35. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis. 2005;41(2):159-166.
36. Kim DH, Spencer M, Davidson SM, et al. Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopedic surgery. J Bone Joint Surg Am. 2010;92(9):1820-1826.
37. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362(1):9-17.
38. Perl TM, Cullen JJ, Wenzel RP, et al. Mupirocin And The Risk Of Staphylococcus Aureus Study Team. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346(24):1871-1877.
39. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis. 2002;35(4): 353-358.
40. Krespi YP, Kizhner V. Laser-assisted nasal decolonization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. Am J Otolaryngol. 2012 Apr 12: (2): 250-399.
41. Immerman I, Ramos NL, Katz GM, Hutzler LH, Phillips MS, Bosco JA III. The persistence of Staphylococcus aureus decolonization after mupirocin and topical chlorhexidine: implications for patients requiring multiple or delayed procedures. J Arthroplasty. 2012;27(6):870-876.
42. Arciola CR, Bustanji Y, Conti M, et al. Staphylococcus epidermidis- fibronectin binding and its inhibition by heparin. Biomaterials. 2003;24(18):3013-3019.
43. Neoh KG, Kang ET. Combating bacterial colonization on metals via polymer coatings: relevance to marine and medical applications. ACS Appl Mater Interfaces. 2011;3(8):2808-2819.
44. Li LL, Wang LM, Xu Y, Lv LX. Preparation of gentamicinloaded electrospun coating on titanium implants and a study of their properties in vitro. Arch Orthop Trauma Surg. 2012;132(6):897-903.
45. Nablo BJ, Rothrock AR, Schoenfisch MH. Nitric oxidereleasing sol-gels as antibacterial coatings for orthopedic implants. Biomaterials. 2005;26(8):917-924.
46. Fu J, Ji J, Yuan W, Shen J. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials. 2005;26(33):6684-6692.
47. Lee DW, Yun YP, Park K, Kim SE. Gentamicin and bone morphogenic protein-2 (BMP-2)-delivering heparinized-titanium implant with enhanced antibacterial activity and osteointegration. Bone. 2012;50(4):974-982.
48. Fielding GA, Roy M, Bandyopadhyay A, Bose S. Antibacterial and biological characteristics of silver containing and strontium doped plasma sprayed hydroxyapatite coatings. Acta Biomater. 2012;8(8):3144-3152.
49. Simchi A, Tamjid E, Pishbin F, Boccaccini AR. Recent progress in inorganic and composite coatings with bactericidal capability for orthopedic applications. Nanomedicine. 2011;7(1):22-39.
50. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54(4):560-567.
51. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346(7):491-496.
52. Montanaro L, Testoni F, Poggi A, Visai L, Speziale P, Arciola CR. Emerging pathogenetic mechanisms of the implantrelated osteomyelitis by Staphylococcus aureus. Int J Artif Organs. 2011;34(9):781-788.
53. Testoni F, Montanaro L, Poggi A, Visai L, Campoccia D, Arciola CR. Internalization by osteoblasts of two Staphylococcus aureus clinical isolates differing in their adhesin gene pattern. Int J Artif Organs. 2011;34(9):789-798.
54. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun. 2011;79(4):1797-1803.
55. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551-1557.
56. Spellberg B, Daum R. A new view on development of aStaphylococcus aureus vaccine: insights from mice and men. Hum Vaccin. 2010;6(10):857-859.
57. Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005;21:319-346.
58. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol. 2001;55:165-199.
59. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295(5559):1487.
60. Montanaro L, Poggi A, Visai L, et al. Extracellular DNA in biofilms. Int J Artif Organs. 2011;34(9):824-831.
61. Nijland R, Hall MJ, Burgess JG. Dispersal of biofilms by secreted, matrix degrading, bacterial DNase. PLoS One. 2010;5(12):e15668.
62. Kaplan JB, LoVetri K, Cardona ST, et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo). 2012;65(2):73-77.
63. Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N. Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother. 2004;48(7): 2633-2636.
64. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother. 2009;64(1):88-93.
65. Kalpana BJ, Aarthy S, Pandian SK. Antibiofilm Activity of alpha-Amylase from Bacillus subtilis S8-18 Against Biofilm Forming Human Bacterial Pathogens. Appl Biochem Biotechnol. 2012;167(6):1778-1794.
66. Hartman MB, Fehring TK, Jordan L, Norton HJ. Periprosthetic knee sepsis. The role of irrigation and debridement. Clin Orthop Relat Res. 1991;(273):113-118.
67. Silva M, Tharani R, Schmalzried TP. Results of direct exchange or debridement of the infected total knee arthroplasty. Clin Orthop Relat Res. 2002;(404):125-131.
68. Sherrell JC, Fehring TK, Odum S, et al. Periprosthetic Infection Consortium. The Chitranjan Ranawat Award: fate of two-stage reimplantation after failed irrigation and débridement for periprosthetic knee infection. Clin Orthop Relat Res. 2011;469(1):18-25.
69. Deirmengian C, Greenbaum J, Lotke PA, Booth RE Jr, Lonner JH. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J Arthroplasty. 2003;18(7)(Suppl 1):22-26.
70. Azzam KA, Seeley M, Ghanem E, Austin MS, Purtill JJ, Parvizi J. Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. J Arthroplasty. 2010;25(7):1022-1027.
71. Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty. 2009;24(6)(Suppl):101-104.
72. Odum SM, Fehring TK, Lombardi AV, et al. Periprosthetic Infection Consortium. Irrigation and debridement for periprosthetic infections: does the organism matter? J Arthroplasty. 2011;26(6)(Suppl):114-118.
73. Crockarell JR, Hanssen AD, Osmon DR, Morrey BF. Treatment of infection with débridement and retention of the components following hip arthroplasty. J Bone Joint Surg Am. 1998;80(9):1306-1313.
74. Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis. 2006;42(4):471-478.
75. Burger RR, Basch T, Hopson CN. Implant salvage in infected total knee arthroplasty. Clin Orthop Relat Res. 1991;(273):105-112.
76. Oussedik SI, Dodd MB, Haddad FS. Outcomes of revision total hip replacement for infection after grading according to a standard protocol. J Bone Joint Surg Br. 2010;92(9): 1222-1226.
77. Singer J, Merz A, Frommelt L, Fink B. High rate of infection control with one-stage revision of septic knee prostheses excluding MRSA and MRSE. Clin Orthop Relat Res. 2012;470(5):1461-1471.
78. Jämsen E, Stogiannidis I, Malmivaara A, Pajamäki J, Puolakka T, Konttinen YT. Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop. 2009;80(1):67-77.
79. Buchholz HW, Elson RA, Engelbrecht E, Lodenkämper H, Röttger J, Siegel A. Management of deep infection of total hip replacement. J Bone Joint Surg Br. 1981;63-B(3):342-353.
80. Iorio R, Healy WL, Presutti AH. A prospective outcomes analysis of femoral component fixation in revision total hip arthroplasty. J Arthroplasty. 2008;23(5):662-669.
81. Yoo JJ, Kwon YS, Koo KH, Yoon KS, Kim YM, Kim HJ. One-stage cementless revision arthroplasty for infected hip replacements. Int Orthop. 2009;33(5):1195-1201.
82. Whiteside LA, Peppers M, Nayfeh TA, Roy ME. Methicillinresistant Staphylococcus aureus in TKA treated with revision and direct intra-articular antibiotic infusion. Clin Orthop Relat Res. 2011;469(1):26-33.
83. Wolf CF, Gu NY, Doctor JN, Manner PA, Leopold SS. Comparison of one and two-stage revision of total hip arthroplasty complicated by infection: a Markov expected-utility decision analysis. J Bone Joint Surg Am. 2011;93(7):631-639.
84. Goldman RT, Scuderi GR, Insall JN. 2-stage reimplantation for infected total knee replacement. Clin Orthop Relat Res. 1996;(331):118-124.
85. Haleem AA, Berry DJ, Hanssen AD. Mid-term to long-term followup of two-stage reimplantation for infected total knee arthroplasty. Clin Orthop Relat Res. 2004;(428):35-39.
86. Mittal Y, Fehring TK, Hanssen A, Marculescu C, Odum SM, Osmon D. Two-stage reimplantation for periprosthetic knee infection involving resistant organisms. J Bone Joint Surg Am. 2007;89(6):1227-1231.
87. Windsor RE, Insall JN, Urs WK, Miller DV, Brause BD. Two-stage reimplantation for the salvage of total knee arthroplasty complicated by infection. Further follow-up and refinement of indications. J Bone Joint Surg Am. 1990;72(2): 272-278.
88. Aslam S, Darouiche RO. Role of antibiofilm-antimicrobial agents in controlling device-related infections. Int J Artif Organs. 2011;34(9):752-758.
89. Hofmann CM, Bednar KJ, Anderson JM, Marchant RE. Disruption of Staphylococcus epidermidis biofilm formation using a targeted cationic peptide. J Biomed Mater Res A. 2012;100(4):1061-1067.
90. Iannitelli A, Grande R, Di Stefano A, et al. Potential Antibacterial Activity of Carvacrol-Loaded Poly(DL-lactide-co-glycolide) (PLGA) Nanoparticles against Microbial Biofilm. Int J Mol Sci. 2011;12(8):5039-5051.
91. Al-Azemi A, Fielder MD, Abuknesha RA, Price RG. Effects of chelating agent and environmental stresses on microbial biofilms: relevance to clinical microbiology. J Appl Microbiol. 2011;110(5):1307-1313.
92. Taylor ZD, Navarro A, Kealey CP, et al. Bacterial biofilm disruption using laser generated shockwaves. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:1028-1032.
93. Kizhner V, Krespi YP, Hall-Stoodley L, Stoodley P. Lasergenerated shockwave for clearing medical device biofilms. Photomed Laser Surg. 2011;29(4):277-282.
94. Wainwright M. Photo dynamic medicine and infection control. J Antimicrob Chemother. 2012;67(4):787-788.
95. Biel MA, Sievert C, Usacheva M, Teichert M, Balcom J. Antimicrobial photodynamic therapy treatment of chronic recurrent sinusitis biofilms. Int Forum Allergy Rhinol. 2011;1(5): 329-334.
96. Zhang A, Sun H, Wang X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem. 2012;404(4):1239-45.
97. Ma Y, Zhang P, Wang F, Liu W, Yang J, Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg. 2012;255(4):720-730.
98. Cohen MJ, Serkova NJ, Wiener-Kronish J, Pittet JF, Niemann CU. 1H-NMR-based metabolic signatures of clinical outcomes in trauma patients-beyond lactate and base deficit. J Trauma. 2010;69(1):31-40.